|Mr. David G. Kalergis||Co-Founder, CEO & Chairman||522.24k||N/A||1949|
|Mr. William Karl Hornung||Chief Financial Officer||265.26k||N/A||1969|
|Mr. Thomas E. Byrne||Gen. Counsel||N/A||N/A||1957|
|Dr. David Randolph Jones M.D.||Sr. Medical Advisor||N/A||N/A||1963|
|Ms. Kelly Hoy||Director of Project Management||N/A||N/A||N/A|
Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer and metastatic brain cancer; and Phase II trial for the treatment of acute stroke. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. was founded in 2001 and is headquartered in Charlottesville, Virginia.
Diffusion Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.